Background. The Enalapril Postinfarction Exercise (EPIE) trial was designed to study the effect of enalapril treatment on peak and submaximal cardiopulmonary exercise performance over the course of 1 year in men after myocardial infarction with mild exercise intolerance.
C onverting enzyme inhibition has been shown to be effective in the management of symptomatic congestive heart failure (CHF).12 Improvements in clinical status,3,4 hemodynamics,5,6 and exercise performance7,8 have been demonstrated, and therapy is associated with a reduction in mortality in patients with severe CHF.9 However, the effect of long-term therapy on the functional capacity of patients with mild exercise intolerance has not been addressed in a large-scale trial.
Inhibition of angiotensin converting enzyme with captopril retarded left ventricular dilatation and improved survival in a rat model after coronary artery ligation.10 In patients after Q wave anterior wall infarction, treatment resulted in reduced echocardiographic11 and angiographic12 left ventricular volume, and this finding was accompanied by improved exercise performance. 13 Assessment of cardiac reserve in patients with mild left ventricular dysfunction may be accomplished by grams22 have demonstrated improvement in peak and submaximal exercise parameters in patients with symptomatic heart failure.
The Enalapril Postinfarction Exercise (EPIE) trial tested the hypothesis that long-term converting enzyme inhibition administered after myocardial infarction (MI) would improve the exercise performance of patients with mildly reduced peak Vo2. One hundred sixty men with a peak Vo2 of less than 25 ml/kg/min were randomized in a double-blind manner to receive enalapril or placebo and were tested nine times during a 48-week period. Group 1 patients (n=100) were randomized 21 days after MI. Group 2 patients (n=60) were randomized at least 6 months after MI.
Methods

Patient Population
One hundred sixty men with documented MI and a peak Vo2 less than 25 ml/kg/min were included in the study. All patients were in New York Heart Association (NYHA) class I or II at entry into the trial. Group 1 consisted of 100 men with a mean age of 60.3+7.6 years and were randomized to receive enalapril or placebo 21 days after MI. Group 2 consisted of 60 men with a mean age of 62.4+7.3 years and were randomized to receive enalapril or placebo at least 6 months after MI. All patients in both groups received long-term timolol therapy for secondary prophylaxis. MI was confirmed by conventional clinical, electrocardiographic, and biochemical criteria. Approximately 240 patients were screened, and 160 patients were included in the study. The screening process was selective in that patients with postinfarction angina, patients intolerant of /3-blockade, and patients requiring therapy for symptomatic heart failure were not eligible for screening. Detailed descriptions of the clinical characteristics of the study populations are provided in Tables 1 and 2 26 We have demonstrated that this method is reproducible and corresponds well to the lactate threshold. 27 The manual method uses a 450 triangle that is brought in from the right parallel to the VCO2 versus Vo2 plot. This facilitates detection of the inflection occurring with a slope greater than 1.0. The computer program automates this method and analyzes the subset of the plot with a work rate greater than 5 W and a respiratory exchange ratio of less than 1.00.
This subset of data was chosen to minimize the obscuring effects of the hyperventilation response at the onset of exercise and the respiratory compensation that usually occurs immediately before termination of peak exercise. A line with a slope of 1.0 (S1) is drawn through the plot such that 5% of the data points lie below the line. The anaerobic threshold is detected at the last inflection of the VCO2 versus Vo2 curve from S1.
Statistical Methods
According to protocol 50 patients per treatment group were required to have an 80% power to detect a difference between the treatment groups of 2.1 ml/kg/min with respect to peak Vo2. This was based on an estimated standard deviation for the change in peak Vo2 of 3.8 ml/kg/min. This estimate was very close to the observed standard deviation that was 3.4 ml/kg/min in the enalapril-treated patients and 3.0 ml/kg/min in the placebo-treated patients.
Fisher's exact test was used to compare the treatment groups with respect to dichotomous variables such as the presence or absence of a specific adverse experience or a physical examination abnormality. with data both at baseline and at the specified time period were included. The second of the two baseline tests was used for all further analysis to ensure familiarity with the testing procedure and to minimize a possible training effect. Results The groups were found to be comparable at baseline with regard to clinical characteristics and exercise performance. The exercise parameters were reproducible. The mean peak Vo2 for the first baseline test in group 1 was 18.5±3.8 versus 19.0±3.7 ml/kg/ min for the second baseline test. The mean change was 0.51 ml/kg/min with a standard deviation of ±1.65 and a correlation coefficient of 0.91. Details are provided for group 1 in Table 1 and for group 2 in Table 2 .
One hundred fifty of the 160 patients that were entered completed the trial according to protocol. The average dose of enalapril was 18.75 mg in group lE and 20 mg in group 2E. There were two deaths in group 1, both in the enalapril group (1E). There were two deaths in group 2, both in the placebo group (2P). Eight patients in group 1 were excluded from further treatment because of possible drug-related side effects: six in group 1E and two in group 1P. In group 2E, two patients were discontinued from further study because of possible drug-related side effects. There were no between-group differences observed during the trial with regard to global evaluation or NYHA function class.
There were no significant differences with regard to resting heart rate or body weight between patients receiving placebo or enalapril in either group observed during the study. In group 1P, resting systolic blood pressure rose significantly from baseline to 48 weeks from 123±18 to 130±19 mmHg (p<0.01).
Resting systolic blood pressure fell in group 1E from 128±20 to 124±21 mm Hg (p<0.01) from baseline to 48 weeks. The between-group difference was significant (p<0.01). In group 2P, resting systolic blood pressure fell by 1.4±+15 mm Hg (NS). The reduction in group 2E was 15.1±18 mmHg (p<0.01). Small, but significant, reductions (p<0.05) in radiographic heart volume were observed in groups 1P (3.1%) and 1E (3.6%). There were no significant differences between groups with regard to any of the laboratory variables measured during the course of the study. Specifically, serum creatinine and serum potassium levels showed no significant within-group change. Details are provided for group 1 in Table 3 and for group 2 in Table 4 .
In Table 5 .
Similarly, in group 2, no statistically significant differences were found between placebo and enalapril subgroups with regard to peak or submaximal exercise performance. The peak respiratory exchange ratio (VCOJVo2) was 1.31±0.11 in 2P and 1.28±0.12 (Figure 2A ). The mean Vo2 at the anaerobic threshold for 2P was 12.1±2.3 at baseline and 13.2±3.4 ml/kg/min at 48 weeks (NS). The corresponding values for the 2E group were 12.1±2.6 at baseline and 12.5±2.6 ml/kg/ min at 48 weeks (NS) ( Figure 2B ). Total exercise time increased in 2P from 677±114 to 682±126 seconds (NS). Total exercise time increased in 2E from 659±99 to 666±+130 seconds (p=NS) ( Figure  2C ). These results are summarized in Table 6 .
Peak heart rate did not differ significantly between baseline and 48 weeks within either group, and no significant between-group differences were observed. In group 1P, peak heart rate was 102±13 at baseline and was 108±15 beats/min at 48 weeks. In group 1E, peak heart rate was 102±11 at baseline and was 104±13 beats/min at 48 weeks. In group 2P, peak heart rate was 102+13 at baseline and was 108+15 beats/min at 48 weeks. In group 2E, peak heart rate was 102± 11 at baseline and was 104± 13 
Discussion
Maximal cardiopulmonary exercise testing has been shown to be a valuable tool in the clinical assessment of functional capacity28 and prognosis.29 It is our experience that peak effort can be more readily achieved in male subjects, and therefore, the EPIE trial limited inclusion to men. Peak oxygen consumption can be reliably achieved in patients with coronary artery disease,30 and we have shown that the results are highly reproducible in such patients. 31 Group 1 patients were randomized at 21 days after MI; the trial was not designed to evaluate the effect of therapy during the acute phase of MI. Early reduction in left ventricular wall stress after converting enzyme inhibition might favorably alter the remodeling process during the acute phase of MI and permit improved functional capacity. Our intention was to evaluate the effect of long-term enalapril treatment on exercise performance in patients with mild exercise intolerance and reduced peak Vo2. We chose to limit inclusion to patients with confirmed MI to obtain a homogenous patient population.
We were unable to detect any differences between the effects of enalapril and placebo on the peak or submaximal cardiopulmonary exercise performance of men with only mildly reduced peak Vo2 after myocardial infarction. Both the placebo-and enalapril-treated patients who were randomized 21 days after MI (group 1) showed improvement in peak Vo2, Vo2 at the anaerobic threshold, and exercise dura- Weeks FIGURE 1. Plots of peak V02, during Vo2 at the anaerobic threshold (AT), and total exercise duration for placebo-and enalapril-treated patients during 48 only observed in the subset of patients with increased left ventricular volumes and severe wall motion abnormalities. As expected, the degree of activation of the renin-angiotensin-aldosterone system in these patients was correlated to the presence of loop diuretic therapy. However, this neurohumoral activation was also correlated to a Killip's classification of more than 2, the presence of more than 30% left ventricular wall akinesis, and the presence of left ventricular aneurysm. 56 Similarly, the baseline neurohumoral data from the Studies of Left Ventricular Dysfunction (SOLVD) indicate that although neurohumoral activation occurs early in asymptomatic patients with ejection fractions less than 35% (prevention arm), this is primarily limited to activation of the sympathetic nervous system and to the release of atrial natriuretic factor and arginine vasopressin.57 The renin-angiotensin-aldosterone system becomes active at a later stage and only when symptomatic heart failure is established, especially in the presence of diuretic therapy (treatment arm).
Our data are compatible with these recent findings. In the EPIE trial, no patients were receiving diuretics, and only 8% of patients in group 1 had echocardiographic evidence of severe left ventricular dysfunction. The mean peak Vo2 values at baseline in the EPIE trial were only 2.0 ml/kg/min less than the mean peak Vo2 values at baseline in the SOLVD prevention arm.58 It is likely, therefore, that very few patients in this study had substantial activation of the reninangiotensin-aldosterone system.
The sample size was adequate, and all 160 patients completed the trial according to the protocol. Nine tests during the course of 1 year ensured familiarity with the testing procedure, and the high peak respiratory exchange ratios confirm maximal effort. The gas-exchange studies were performed with rigorous detail.25'27,3' All patients had documented MI and only mildly reduced peak exercise performance. Although the patient population was heterogeneous with regard to MI type, localization, and the degree of wall motion abnormality, the subset with substantial left ventricular dysfunction was small.
The results of the EPIE trial suggest that long-term converting enzyme inhibition will not improve mildly reduced exercise capacity in men with coronary artery disease and recent MI. Further attention should be directed toward evaluating the efficacy of converting enzyme inhibition therapy in more symptomatic patients with greater myocardial injury and moderately reduced exercise performance in an attempt to correctly profile patients likely to profit from intervention.
